Ashish Kacholia and Samara Capital support Sahajanand Medical Technologies Files, DRHP for IPO

Sahajanand Medical Technologies (SMT) Limited has filed its draft Red Harring Prospectus (DRHP) to raise funds by the initial public offer (IPO) route.

With the face value of the IPO, RE1, the promoters and investors are offer-for-sales (OFS) up to 27,644,231 equity shares by shareholders selling. This offer includes a subscription reservation with discounts to eligible employees in the employee reservation part.

Samara Capital Markets Limited, Kotak Pre-IPO Opportunities Fund, Plutus Wealth Management LLP and Ashish Kacholia are the main shareholders of the company.

In the OFS, Mr. Hari Trust, Dhirjakumar Savjibhai Vasoya will reach 2,700,000 equity shares, 12,958,126 equity shares by Samara Capital Markets Limited, 2,615,750 equity shares, and 2,615,750 equity shares, and 6,670,35555555555555555555555555555555555555555555555555555555555555555555555555555555555555555 5555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555555.

This offer is being done by the fur book-building process, with no more than 50% of the allotted to qualified institutional buyers, and less than 5% and% 35% of the offer fur is not assigned to non-institutional and retail personal bidders, respectively.

Sahajanand Medical Techniques

Sahajanand Medical Technologies is a Class III and Class C/D Medical Device Company with a portfolio of technically advanced medical devices of vascular and structural heart intervention.

Sahajanand Medical Technologies was founded by Dhirjalal Kotadia in 2001 and over the years, by March 31, 2025, in 76 countries, has introduced many innovative products, focusing on research and development and precision production capabilities to deliver quality products supported by clinical data.

Its portfolio includes coronary stents and coronary intervention products such as coronary balloons, SH products include trans-coriander aortic valves and oculiders, and their own brand of renal stents, peripheral drug coated balloons and other trading products.

According to the F&S report, it is a major part of the market in the drug alluting stent (DES) market in India, with a market share of about 25.00% in CY 2025 of the total DES sales volume in India.

SMT

SMT Limited’s revenue from operation increased 13.67% in FY 2025 in FY 2025 to Rs. 1,024.88 crore, which mainly increased the sales of high -sales devices in Europe and mainly led by the structural heart vertical in the rest of the world. In the financial year 2024, the profit for the year in the financial 2025 is Rs. It was 25.15 crore.

Head administrators

Motilal Oswal Investment Advisors Limited, Avendes Capital Private Limited, HSBC Securities and Capital Markets (India) Private Limited and Navama Wealth Management Limited are the lead managers and MUFG Intim India Private.

Equity stocks are proposed to be listed on National Stock Exchange India for India Limited and BSE Limited.

Also Read: Sas Unicorn Amagi Media Labs DRHP with SEBI, Rs. DRHP to collect 1,020 crores

(Connection: The recommendations, suggestions, opinions and opinions provided by experts have their own. This does not represent opinions of economic time)